Refractory High Blood Pressure and White Coat Hypertension

The article defines resistant hypertension as blood pressure that remains high despite the use of three or more medications. In contrast, researchers describe refractory hypertension as a more severe failure where patients do not achieve target levels even with five or more drug classes, including specific diuretics like chlorthalidone and spironolactone. While 10–20% of hypertensive individuals meet the criteria for resistant hypertension, true refractory cases remain rare, affecting less than 5% of patients in specialty clinics.

Mechanistic differences distinguish these two phenotypes. Resistant hypertension typically involves excess fluid retention, so physicians often successfully treat it by intensifying diuretic therapy. Refractory hypertension appears more neurogenic, meaning patients exhibit higher sympathetic activity, elevated resting heart rates, and increased vascular resistance.

Clinicians must distinguish “true” treatment failure from pseudoresistance. A critical factor involves white coat hypertension, a condition where patients show high blood pressure in the office but maintain controlled levels during ambulatory monitoring. Studies show that the white coat effect accounts for approximately 37% to 38% of apparent resistant hypertension cases. Evidence also suggests that a significant white coat effect occurs even more frequently in the refractory phenotype than in the broader resistant population, though researchers have not yet quantified the exact prevalence for this specific group.

Both conditions share risk factors like African ancestry and chronic kidney disease. However, the refractory phenotype specifically affects younger patients and women, particularly African American women. Ultimately, identifying white coat hypertension and verifying medication adherence allows specialists to avoid unnecessary treatments and focus on appropriate strategies, such as sympatholytic approaches for neurogenic cases.